Bicycle Therapeutics plc
BCYC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12 | $3 | $10 | $4 |
| % Growth | 301.8% | -70.7% | 169.1% | – |
| Cost of Goods Sold | $0 | $71 | $57 | $56 |
| Gross Profit | $12 | -$68 | -$47 | -$52 |
| % Margin | 100% | -2,332.5% | -474% | -1,412.2% |
| R&D Expenses | $58 | $71 | $59 | $50 |
| G&A Expenses | $19 | $19 | $21 | $21 |
| SG&A Expenses | $19 | $19 | $21 | $21 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | -$0 | -$72 | -$57 | -$56 |
| Operating Expenses | $77 | $18 | $23 | $15 |
| Operating Income | -$66 | -$87 | -$70 | -$68 |
| % Margin | -558.6% | -2,965.8% | -703.7% | -1,824.8% |
| Other Income/Exp. Net | $7 | $7 | $8 | $15 |
| Pre-Tax Income | -$59 | -$79 | -$62 | -$53 |
| Tax Expense | $0 | -$0 | -$1 | -$1 |
| Net Income | -$59 | -$79 | -$61 | -$52 |
| % Margin | -503.7% | -2,703.8% | -608.9% | -1,398.4% |
| EPS | -0.85 | -1.14 | -0.88 | -0.74 |
| % Growth | 25.4% | -29.5% | -18.9% | – |
| EPS Diluted | -0.85 | -1.14 | -0.88 | -0.74 |
| Weighted Avg Shares Out | 69 | 69 | 69 | 69 |
| Weighted Avg Shares Out Dil | 69 | 69 | 69 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7 | $8 | $10 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | -$8 | $2 |
| EBITDA | -$57 | -$77 | -$70 | -$66 |
| % Margin | -486.6% | -2,651.8% | -703.7% | -1,778.8% |